Introduction
Papillary thyroid carcinomas (PTC) are the most common thyroid cancers and constitute more than 70% of all thyroid malignancies [1] . Classification of thyroid lesion is critical for prognosis and treatment selection, hence the distinction of PTC from other malignant and benign thyroid lesions has important implications for clinical management. Diagnosis of PTC is based on its histological pattern involving specific papillary architecture, yet some papillary carcinomas show not the typical histological features [2, 3] . Moreover, diagnosis of thyroid cancers is initially based on the fine needle aspiration cytology of thyroid nodules [4] . However, morphology-based methods have several limitations restricting correct classification of cancer subtypes [5, 6] . Hence, classification of different thyroid cancer subtypes could be facilitated if histological/cytological patterns were supported by molecular biomarkers.
Lipids are among classes of biomolecules with a high potential value in cancer diagnostics [7] . Phospholipids, which are the major constituents of cell membranes, play an important role in signal transduction, inflammation, cell proliferation and differentiation [8] [9] [10] , and influence key aspects of cancer phenotype [11, 12] . A few papers have reported differences in the lipid profiles of thyroid neoplasms [13] [14] [15] [16] , hence this class of compounds could be potentially implemented in classification of thyroid lesions. Mass spectrometry imaging (MSI) is a newly developed technique allowing for determination of spatial distribution of metabolites and lipids within the tissue sections [17] [18] [19] [20] . An important advantage of molecular profiling by MSI lays on its ability to use spectra exported from specific tissue areas defined by a pathologist based on their morphological features, which might be called a "virtual microdissection". Formalin fixation (FF) is a standard procedure for stabilization and preservation of tissue specimens for clinical purposes. However, fixation process impairs the ability to analyse certain classes of biomolecules [21, 22] . Recently, we demonstrated that tissues fixed with formalin and processed without paraffin embedding were suitable for imaging of lipids by MALDI (matrix--assisted laser-desorption ionization)-MSI [23] . In the present study this approach was used for profiling of lipids in FF tissue to detect species discriminating PTC from non-cancerous thyroid.
Material and methods

Clinical material
Tissue samples were collected from 3 Caucasian patients with PTC treated in Maria Sklodowska-Curie Institute (Gliwice, Poland). Samples were obtained from a cancer and adjacent non-cancerous thyroid tissue immediately after tumour resection. Detailed information on clinical samples is given in the Supplementary Table sI. Immediately after resection tissue specimens were fixed in neutral buffered formalin (4% formaldehyde in phosphate buffer, pH 7.0) for 24 hours at room temperature, and stored in -80°C until analysed. Some of the tissue samples were also frozen in liquid nitrogen.
Tissue sample preparation and matrix deposition
Ten µm thick tissue sections were prepared using a cryostat, and then serial sections were mounted onto indium tin oxide (ITO) either coated glass slides (Bruker, Germany) for MSI or standard glass slides for hematoxylin and eosin (H&E) staining. Each tissue section for MSI was washed twice with distilled water (2 × 30 seconds), and then covered with a-cyano-4-hydroxycinnamic acid (CHCA) matrix solution (0.5% a-cyano-4-hydroxycinnamic acid in 70% methanol and 0.2% trifluoroacetic acid) in a series of 4 layers (5 µL/min) using SunCollect Instrument (SunChrom, Germany).
Mass spectrometry analysis
Mass spectrometry imaging was performed using a HDMS SYNAPT TM G2 system and Driftscope 2.1 software (Waters, UK). Mass spectrometry (MS) and tandem mass spectrometry (MS/MS) data were acquired in positive ion sensitivity mode at a mass resolution of 10 000 full width at half maximum (FWHM) with ion mobility separation enabled and over the mass range m/z 100 to 1200. Image acquisition was performed using raster imaging mode at 100 μm spatial resolution, Biomap 3.7.5.5 software (http://www.maldi-msi.org/) was used for image generation. The MS/MS spectra were acquired manually moving the laser position and adjusting the collision energy to achieve good signal to noise for product ions across the full m/z range of the spectrum. Collision energies were adjusted from 25 to 40 eV during acquisition and acquisition times were generally of the order of 5-10 s per spectrum. Lipids were identified by the comparison of the exact molecular masses and fragmentation pathways of the protonated molecule ions, recorded during the MS/ MS experiments, with LIPIDMAPS database (www. lipidmaps.org) Positive identification of molecular ions was assumed if a unique match with error below 3 ppm was found.
Statistical analysis
Mass spectra were pre-processed and spectral components were detected using the Gaussian Mixture Model as described in details elsewhere [24] . Due to significant deviations from normal distribution the nonparametric Kruskal-Wallis ANOVA was used to check 
Results
Cancer and non-cancerous regions of interest (ROIs) were defined by a pathologist in the tissue specimen from each patient and 100 spectra were imported from each ROI (average mass spectra from each ROI are presented in Fig. 1 ); 476 components representing molecular species with their isotopic envelopes were detected in the 700-900 Da mass range. For each pair of ROIs the statistical significance of differences in abundance of each spectral component was estimated (numbers of differentiating components are listed in Table I ). The average number of differentiating components between paired cancer and noncancerous ROIs was 229. On the other hand, average number of differentiating components among all cancer ROIs was 232, while average number of differentiated components among all noncancerous ROIs was 281. This might suggest a higher degree of similarity among PTC from different patients than among non-cancerous thyroid regions from different patients. However, this unexpected observation could be explained when considering that "non-cancerous" regions include one "normal" thyroid tissue (Patient_2) and two non-cancerous thyroid diseases: nodular goiter (Patient_1) and lymphocytic thyroiditis (Patient_3 . In general, we observed the same molecular ions corresponding to lipid species in formalin-fixed and fresh-frozen thyroid tissue, yet sodium adducts were the most abundant in the former material whereas potassium adducts predominated in the latter type of material. Moreover, the abundance of registered ions was higher in fresh-frozen tissue ( Supplementary Fig. s1 ). Hence, to verify the identity of detected lipids selected components were analysed by in tissue MS/MS in corresponding fresh-frozen cancerous tissue (Supplementary Fig. s2 , Tab. sII). This analysis allowed the validation of the identity of 26 molecular ions. Abundances of all 22 identified lipid species detected in thyroid tissue were compared pairwise in cancer and non-cancerous ROI for each patient separately (Table II) . There were 13 lipid species (with 25 molecular ions) that showed cancer-upregulation in all 3 patients. Furthermore, increased abundance of 8 lipids in cancerous tissue was highly statistically significant, which included: phosphatidylcholines PC(32:0), PC(32:1), PC(34:1) and PC(36:3), phosphatidic acids PA(36:2) and PA(36:3), and sphingomyelins SM(34:1) and SM(36:1) (Fig. 2) . This is noteworthy, in that several lipid species were not upregulated in cancerous thyroid when compared to colloid nodular goiter (Patient_1), which represents a benign thyroid neoplasm. Hence, these lipids did A few papers have previously reported specific differences in lipid profiles between thyroid malignancies and non-cancerous thyroid, however in these studies chemically fixed tissue was not employed. Increased abundances of PC(34:1), PC(34:2) and SM(34:1) were observed in PTC when compared to healthy thyroid [17] . Moreover, PC(34:1), PA(36:3) and SM(34:1) could discriminate between thyroid cancers (PTC and FTC), benign thyroid neoplasms and normal thyroid [19] . Furthermore, increased levels of lipids with monounsaturated acyl chains relative to polyunsaturated lipid species were found to be characteristic of the thyroid cancer microenvironment [20] .
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Conclusions
Here we performed profiling of lipid species in formalin-fixed thyroid tissue, proving that this type of clinical material is compatible with mass spectrometry (MS)-based metabolomics/lipidomics studies. Several phosphatidylcholine, sphingomyelin and phosphatidic acid species were identified and quantified in analysed tissues. It was found that eight phospholipids, including PC(32:0), PC(32:1), PC(34:1), PC(36:3), PA(36:2), PA(36:3), SM(34:1) and SM(36:1), were upregulated in PTC and could be used to discriminate this malignancy from non-malignant thyroid tissue, either "normal" or benign neoplasm. This observation validated and further extended previous reports [17, 19] . Furthermore, several other lipid species that could putatively discriminate normal thyroid (either healthy or inflammatory) from benign thyroid neoplasms were detected. Hence, we confirmed that lipid profiling by MALDI-MSI could be potentially used for classification and differentiating diagnosis of thyroid diseases based on clinically relevant material (formalin-fixed tissue).
An advantage of this MSI approach in comparison to other MS-based analytical techniques lays in its unique ability to "extract" molecular information from small defined tissue regions. This is particularly helpful in cases where several distinct diseases co-exist within the same tissue specimen.
